Get started
Author

Joachim Baumgart

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
2019 · Dietrich Wilhelm Beelen, Rudolf Trenschel, et al. · The Lancet Haematology · 173
DNA alkylation and interstrand cross-linking by treosulfan
1998 · J A Hartley, C C O’Hare, et al. · British Journal of Cancer · 125
PDF
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
1998 · A Korfel, M E Scheulen, et al. · PubMed · 114
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
2000 · M E Scheulen, R A Hilger, et al. · PubMed · 112
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.
1998 · C V Christodoulou, D R Ferry, et al. · Journal of Clinical Oncology · 108
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications
2004 · D W Beelen, R Trenschel, et al. · Bone Marrow Transplantation · 100
Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
2010 · Jochen Casper, Daniel Wolff, et al. · Journal of Clinical Oncology · 96
PDF
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial
2011 · T. Ruutu, L. Volin, et al. · Haematologica · 83
PDF
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
2022 · Dietrich W. Beelen, Matthias Stelljes, et al. · American Journal of Hematology · 77
PDF
Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors
1998 · Ralf Axel Hilger, Andreas Harstrick, et al. · Cancer Chemotherapy and Pharmacology · 65
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning
2011 · J Casper, J Holowiecki, et al. · Bone Marrow Transplantation · 57
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society)
2000 · K. Mross, P. Robben-Bathe, et al. · Oncology Research and Treatment · 57
Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2014 · Boglarka Gyurkocza, Jonathan Gutman, et al. · Transplantation and Cellular Therapy · 55
PDF
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
2005 · Alexander Schmittel, Max E. Scheulen, et al. · Melanoma Research · 53
Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model
2004 · Rob E Ploemacher, Kevin W Johnson, et al. · Transplantation and Cellular Therapy · 51
PDF
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)
2003 · I. Fichtner, M. Becker, et al. · European Journal of Cancer · 41
Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
2020 · Krzysztof Kalwak, Monika Mielcarek, et al. · Bone Marrow Transplantation · 39
PDF
Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice
2016 · Sabine M. Poppenborg, Julia Wittmann, et al. · European Journal of Pharmaceutical Sciences · 36
Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1
2004 · Ralf Schmidmaier, Mark Oellerich, et al. · Experimental Hematology · 36
Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2017 · H. Joachim Deeg, Emily A. Stevens, et al. · Transplantation and Cellular Therapy · 32
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial
2023 · Karl-Walter Sykora, Rita Beier, et al. · Bone Marrow Transplantation · 30
PDF
Physicochemical characterization of substituted chromeno[4,3-b][1,5]benzodiazepine stereoisomers designed as cell membrane active antitumor agents
1990 · Walter Werner, Joachim Baumgart, et al. · Biophysical Chemistry · 29
Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients
2003 · Gerold Meinhardt, Farshid Dayyani, et al. · British Journal of Haematology · 27
PDF
Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer
2000 · Ralf Axel Hilger, Gabriele Jacek, et al. · Cancer Chemotherapy and Pharmacology · 25
A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer
2009 · A. Harstrick, H. Wilke, et al. · Onkologie · 24
Works count: 67
Citation count: 1,834
H-index: 24
I10-index: 33
Year
Topic
Type